Iron chelation regulates cyclin D1 expression via the proteasome: A link to iron deficiency-mediated growth suppression

Blood

Volumn 109, Issue 9, 2007, Pages 4045-4054

  Nurtjahja Tjendraputra, Effie ^a,b   Fu, Dong ^b   Phang, Juanita M ^a   Richardson, Des R ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 1 NAPHTHYLALDEHYDE ISONICOTINOYL HYDRAZONE; CYCLIN D1; DEFEROXAMINE; GLYCOGEN SYNTHASE KINASE 3BETA; HYDRAZONE DERIVATIVE; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL SYNCHRONIZATION; CONTROLLED STUDY; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INCUBATION TIME; IRON CHELATION; IRON DEFICIENCY; IRON DEPLETION; IRON THERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; UBIQUITINATION;

EID: 34247373460     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-10-047753     Document Type: Article

References (71)

1. Hershko C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin Haematol. 1994;7:965-1000.
2. Buss JL, Torti FM, Torti SV. The role of iron chelation in cancer therapy. Curr Med Chem. 2003;10:1021-1034.
3. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005;57:547-583.
4. Andrews NC. Disorders of iron metabolism. New England J Med 1999;341:1986-1995.
5. Thelander L, Reichard, P. The reduction of ribonucleotides. Annu Rev Biochem. 1979;48:133-158.
6. Green DA, Antholine WE, Wong SJ, Richardson DR, Chitambar CR. Ribonucleotide reductase as a preferential target for the inhibition of leukemic cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class. Clin Cancer Res 2001;7:3574-3579.
7. Le NTV, Richardson, DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 2002;1603:31-46.
8. Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994;79:551-555.
9. Kulp KS, Green SL, Vulliet PR. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp Cell Res. 1996;229:60-68.
10. Gao J, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood. 2001;98:842-850.
11. Donnellan R, Chetty, R. Cyclin D1 and human neoplasia. Mol Pathol. 1998;51:1-7.
12. Burnworth B, Popp S, Stark HJ, et al. Gain of 11q/cyclin D1 overexpression is an essential early step in skin cancer development and causes abnormal tissue organization and differentiation. Oncogene. 2006;25:4399-4412.
13. Schrump DS, Chen A, Consoli U. Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther. 1996;3:131-135.
14. Diehl JA, Cheng M, Roussenl MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12:3499-3511.
15. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 2000;19:2056-2068.
16. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation by the ubiquitin-proteasome pathway. Genes Dev. 1997;11:957-972.
17. Luo H, Zhang J, Dastvan F, et al. Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest. J Virol. 2003;77:1-9.
18. Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Mol Cell Biol. 2005;25:1100-1112.
19. Rosenwald IB, Kaspar R, Rousseau D, et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem. 1995;270:21176-21180.
20. Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E. Post-translational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci U S A. 1997;94:12070-12074.
21. Newman R, Mobascher A, Mangold U, et al. Antizyme targets cyclin D1 for degradation. J Biol Chem. 2004;279:41504-41511.
22. Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 2002;62:3014-3019.
23. Zatyka M, da Silva NF, Clifford SC, et al. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression of array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 2002;62:3803-38011.
24. Baba M, Hirai S, Yamada-Okabe H, et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of cyclin D1 expression through hypoxia-inducible factor. Oncogene. 2003;22:2728-2738.
25. Murakami Y, Hayashi S. Role of antizyme in degradation of ornithine decarboxylase in HTC cells. Biochem J. 1985;226:893-896.
26. Murakami Y, Matsufuji S, Kameji T, et al. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature. 1992;360:597-599.
27. Tsvetkov P, Asher G, Reiss V, Shaul Y, Sachs L, Lotem J. Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci U S A. 2005;102:5535-5540.
28. Asher G, Bercovich Z, Tsvetkov P, Shaul Y, Kahana C. 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Mol Cell. 2005;17:645-655.
29. Richardson DR, Bernhardt PV. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity. J Biol Inorg Chem. 1999;4:266-273.
30. Chowdary DR, Dermody JJ, Jha KK, Ozer HL. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol. 1994;14:1997-2003.
31. Le NTV, Richardson, DR. Iron chelators with high anti-proliferative activity up-regulate the expression of a growth inhibitory and metastasis supressor gene: a novel link between iron metabolism and proliferation. Blood. 2004;104:2967-2975.
32. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent anti-tumor activity: agents that overcome resistance to chemotherapeutics. Proc Natl Acad Sci U S A. 2006;103:14901-14906.
33. Huang JW, Shiau CW, Yang YT, et al. Peroxisome proliferator-activated receptor g-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol. 2005;67:1342-1348.
34. Richardson DR, Milnes, K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood. 1997;89:3025-3038.
35. Darnell G, Richardson DR. The potential of analogues of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents, III: the effect of the ligands on molecular targets involved in proliferation. Blood. 1999;94:781-792.
36. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents. Blood. 1995;86:4295-4306.
37. Liang S, Richardson DR. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis. 2003;24:1601-1614.
38. Lovejoy DB, Richardson DR. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate high anti-proliferative activity that is selective for tumor cells. Blood. 2002;100:666-676.
39. Le NTV, Richardson DR. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor, p21WAF1/CIP1, but paradoxically inhibits translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis. 2003;24:1045-1058.
40. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol. 2000;20:3224-3233.
41. Shang X, Shiono Y, Fujita Y, Oka S, Yamazaki Y. Synergistic enhancement of apoptosis by DNAand cytoskeleton-damaging agents: a basis for combination chemotherapy of cancer. Anticancer Res. 2001;21:2585-2589.
42. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Graslund A, Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem. 1993;268:26200-26205.
43. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem. 1996;271:20291-20299.
44. Richardson DR, Baker E. Two mechanisms of iron uptake from transferrin by melanoma cells: the effect of desferrioxamine and ferric ammonium citrate. J Biol Chem. 1992;267:13972-13979.
45. Nurse P. Ordering S phase and M phase in the cell cycle. Cell. 1994;79:547-550.
46. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclin D1 and E with an inducible system. Mol Cell Biol. 1994;14:1669-1679.
47. Nasmyth K. Viewpoint: putting the cell cycle in order. Science. 1996;274:1643-1645.
48. Kip1. Biochem Biophys Res Comm. 2001;282:853-860.
49. Guo Y, Harwalkar J, Stacey DW, Hitomi M. Destabilization of cyclin D1 message plays a critical role in cell cycle exit upon mitogen withdrawal. Oncogene. 2005;24:1032-1042.
50. Brodie C, Siriwardana G, Lucas J, et al. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res. 1993;53:3968-3975.
51. Lederman HM, Cohen A, Lee JW, Freedman MH, Gelfand EW. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood. 1984;64:748-753.
52. +)-induced cell cycle arrest. J Biol Chem. 2004;279:38710-38714.
53. Carlson B, Lahusenm T, Singh S, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 1999;59:4634-4641.
54. Zou Y, Ewton DZ, Deng X, Mercer SE, Friedman E. Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J Biol Chem. 2004;279:27790-27798.
55. Lee DH, Goldberg, AL. Proteasome inhibitors: valuable new tools for cell biologist. Trends Cell Biol. 1998;8:397-403.
56. Nencioni A, Garuti A, Schwarzenberg K, et al. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol. 2006;36:681-689.
57. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004;5:417-421.
58. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6:1664-1668.
59. 2 sensing. Science. 2001;292:464-468.
60. 2-regulated prolyl hydroxylation. Science. 2001;292:468-472.
61. Germain D, Russell A, Thompson A, Hendley J. Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286. J Biol Chem. 2000;275:12074-12079.
62. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology. 2004;145:5439-5447.
63. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
64. Huang JW, Shiau CW, Yang J, et al. Development of small-molecule cyclin D1-ablative agents. J Med Chem. 2006;49:4684-4689.
65. Abeysinghe RD, Greene BT, Haynes R, et al. p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis. 2001;22:1607-1614.
66. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425-479.
67. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002;82:373-428.
68. Hipp MS, Kalveram B, Raasi S, Groettrup M, Schmidtke G. FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol. 2005;25:3483-3491.
69. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene. 2002;21:8852-8861.
70. Jiao Y, Wilkinson JT 4th, Christine Pietsch E, et al. Iron chelation in the biological activity of curcumin. Free Radic Biol Med. 2006;40:1152-1160.
71. Arnold M, Papanikolaou, A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005;23:4215-4224.